CBD

New York biotech company trades $60 million in stock for CBD group

Share this:

New York-based biotech company 22nd Century Group, Inc. said it has started integration with GVB Biopharma after swapping $60-65 million in stock for 100% of the Las Vegas-based CBD company in April.

James A. Mish, 22nd Century Group’s CEO, previously suggested the acquired company could generate positive cash flow “in the near term,” and double his company’s income, pegged at ~$31 million in 2021.

The acquisition will “add significant commercial scale to 22nd Century’s existing hemp/cannabis franchise,” GVB said in a press release.

A penny stock traded on NASDAQ, 22nd Century Group is an agriculture biotech company with interests in reduced-nicotine tobacco, hemp, marijuana and hops. The company claims it sold more than five billion doses of CBD last year.

A decade of losses

22nd Century Group, which also owns Goodrich Tobacco Company, LLC, suffered losses of ~$33 million last year, according to its most recent annual report, and had further losses of $8.9 million in Q1 2022. Past yearly reports show the company has consistently lost millions each year since going public in 2011.

GVB provides drug development services and is a contract supplier of CBD and other hemp derivatives to the pharmaceutical and consumer goods industries. The company has said it expects 2022 revenue of roughly $48 million, up from ~$31 million (+58%) the year previous. William Swindells of GVB, which is private, told HempToday that the company is “cash positive,” but did not indicate if it is profitable.

Aggressive push in UK

22nd Century may be banking, in part, on GVB’s aggressive push to claim a part of the UK’s growing CBD market, estimated at £690 million (~€814.5 million; ~$905.7 million) in 2021. GVB claimed in a press release April 7, 2022 that it is the largest supplier of white-label CBD formulations on a list of CBD products preliminarily approved by the UK’s Food Safety Agency (FSA) last month, with most of those coming through RX Pharmaceutical, a separate company based in the UK with which GVB does business.

RX Pharmaceutical topped the FSA list, being associated with 431 products among a total of roughly 6,000 still “live” in FSA’s approval process for new or “novel” foods. The company entered its products in the UK’s CBD sweepstakes through EIHA Projects GmbH, a consortium organized by the European Industrial Hemp Association.

GVB and RX operate independently but expect to merge in the near future, according to Swindells. The company is also pursuing other partnerships in Europe, Swindells added. GVB has “multiple international joint ventures in Europe to co-develop and co-own processing and distribution companies,” according to the press release.

Recent Posts

Cops can’t charge delta-8 stakeholders, but hemp licensees at risk in Kentucky

A judge in Kentucky has barred law enforcement from meddling in the production and sale…

August 8, 2022

Zimbabwe opens domestic market for CBD as traditional herbal medicine

Zimbabwe has opened up the domestic market for CBD as a traditional herbal medicine, expanding…

August 3, 2022

UK Parliamentary group’s curious fantasy: 220,000 hectares of hemp by 2027

The UK's All-Party Parliamentary Group (APPG) on CBD Products has taken direct aim at its…

August 2, 2022

Ahead for the industry: Fiber and food, sure, but hemp will be relegated to a ‘specialty crop’

[Last of three parts] Despite the cloud that has descended over U.S. Hemp, a dwindled…

July 29, 2022

Charlatans, lack of leadership, bureaucracy brought U.S. Hemp down to earth

[Second of three parts] When it comes to the smackdown suffered by the U.S. hemp…

July 27, 2022

With CBD gold rush over, U.S. Hemp is but a shadow of its former self

[First of three parts] As the gold rush in the CBD sector appears headed for…

July 25, 2022